SPA-agreed trial met primary and all secondary endpoints No new or unexpected safety signals in the Mycapssa treated patients 90% of the patients treated with Mycapssa who completed the 36-week study ...
NEEDHAM, Mass., June 26, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial stage biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) approved ...
Chiasma has released phase 3 data supporting its belief that acromegaly patients will prefer to take its oral formulation over existing long-acting injectables. The oral formulation, Mycapssa, came to ...
Nearly four years ago, the FDA left for dead Chiasma's pill for abnormal limb and organ growth based on concerns over the design of a late-stage pivotal trial. But now that Chiasma has picked itself ...
NEWTON, Mass. and JERUSALEM, Israel, Aug. 10, 2015 /PRNewswire/ -- Chiasma, Inc., a U.S. late-stage biopharmaceutical company developing octreotide capsules for the orphan condition acromegaly, today ...
Commercial-stage biopharmaceutical company Chiasma Inc. (CHMA) announced Q1 results and has also agreed to merge with Amryt Pharma. After jumping 46% on the merger announcement yesterday, shares of ...
NEEDHAM, Mass., Aug. 31, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial stage biopharmaceutical company utilizing its delivery platform technology to develop oral therapies to ...
NEWTON, Mass. and JERUSALEM, March 16, 2015 /PRNewswire/ -- Chiasma, Inc., a U.S. privately-held biopharma company developing octreotide capsules, its lead product for the orphan condition acromegaly, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results